The eClinical trial technologies market is set to reach $1.37 billion USD by 2018. The driving forces behind this surge are the need to optimize the drug development process through real‐time data analysis and while cutting costs along the way. While various sectors such as small and large pharmaceutical companies, biotechnology companies and medical device…
October is Breast Cancer Awareness Month, and CROS NT is addressing the implications of conducting clinical studies in breast cancer and how Sponsors can implement smart designs and strategies to conduct more efficient trials. Oncology is perhaps the most complex therapeutic area in clinical trials with over 450 indications and various unique characteristics like slow…
Risk-based Monitoring (RBM) of clinical trials is an approach that combines on-site monitoring along with centralized remote monitoring by coordinating centers. Based on risk assessments about how the clinical information is captured and protocol designed, risk-based monitoring activities can be proactively supported by the usage of reporting tools. CROS NT discusses the considerations and impact…
Statistics play a crucial role in clinical trials and in the drug development process – from trial design to protocol development. Having a fundamental understanding of statistical issues can uphold the integrity of a clinical trial and improve communication between clinicians and statisticians. As a clinical trial professional, non-statistician, are you familiar with the following…